Finally, we reported the frequency of BCR-ABL1 TKD mutations and the impact of clinical important TKD mutations on molecular response to TKIs treatment in Thai patients with CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.